Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala

N/ATerminatedNCT03209128

Centre Francois Baclesse, Luxembourg11 enrolled

Overview

Hippocampus and amygdala are parts of the brain involved in the recognition of emotions, memories, memory, language ... It is therefore very important to protect them during irradiation of the brain. The aim of this study is to evaluate cerebral irradiation with saving hippocampus and amygdala protects these brain functions in patients with small cell lung cancer (SCLC) Radiotherapy of the brain

Study Type

OBSERVATIONAL

Enrollment

Conditions

Non Small Cell Lung Cancer

Interventions

Irradiation prophyllactique cérébraleRADIATION

Irradiation prophyllactique cérébrale

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients over 18 years of age * Patients with a limited SCLC demonstrated histologically responsive or stable to radiochemotherapy or patients with a histologically proven extended SCLC responding to chemotherapy. * WHO Performance Index 0-1 and / or Karnovsky Index\> 70 * Possibility of long-term monitoring Exclusion Criteria: * Concomitant chemotherapy * Impossibility of performing an MRI or CT without injection * Presence of cerebral metastases * History of cerebral irradiation at any time * Patient suffering from severe collagenosis * Patient with cognitive disorders with MMSE score \<24

Locations (1)

Centre Francois Baclesse

Esch-sur-Alzette, Luxembourg

Outcomes

Primary Outcomes

Cognitive function

Evaluate the cognitive function with Wechsler Memory Scale IV (WMS-IV) test

Time frame: until 18 months after inclusion of patient

Secondary Outcomes

Secondary effects according the CTCAE v.4 criteria

Evaluate the toxicity according the CTCAE v.4 criteria

Time frame: until 18 months after inclusion of patient

Appearance of brain metastases and their location

Evaluate the brain control with brain MRI

Time frame: until 18 months after inclusion of patient

Quality of life (QOL) of patients

Evaluate QOL with FACT-BR test (Functional Assessment of Cancer Therapy-Brain)

Time frame: until 18 months after inclusion of patient

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.